Neuronetics Inc
STIM
View Detailed Chart
2.909USD
+0.059+2.06%
Market hours （ET）Quotes delayed by 15 min
192.30MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.06%
5 Days
-15.69%
1 Month
-12.92%
6 Months
-42.52%
Year to Date
+80.66%
1 Year
+205.56%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
6.500
Target Price
+134.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Neuronetics, Inc. is a medical technology company focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its NeuroStar Advanced Therapy for Mental Health is a non-drug, noninvasive treatment for people suffering from neurohealth conditions. In addition to selling the NeuroStar system and associated treatment sessions to customers, it operates treatment centers across the United States, offering both NeuroStar Advanced Therapy (transcranial magnetic stimulation or TMS) and Spravato (esketamine nasal spray) for the treatment of major depressive disorder (MDD) and other mental health disorders. NeuroStar Advanced Therapy is the TMS treatment for MDD in adults. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. It provides more than 1.68 million treatments to over 51,000 patients struggling with depression.
Growing
The company is in a growing phase, with the latest annual income totaling USD 74.89M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 17.62.
Fairly Valued
The company’s latest PE is -2.52, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 47.56M shares, decreasing 7.81% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.74M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.95.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Neuronetics, Inc. is a medical technology company focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its NeuroStar Advanced Therapy for Mental Health is a non-drug, noninvasive treatment for people suffering from neurohealth conditions. In addition to selling the NeuroStar system and associated treatment sessions to customers, it operates treatment centers across the United States, offering both NeuroStar Advanced Therapy (transcranial magnetic stimulation or TMS) and Spravato (esketamine nasal spray) for the treatment of major depressive disorder (MDD) and other mental health disorders. NeuroStar Advanced Therapy is the TMS treatment for MDD in adults. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. It provides more than 1.68 million treatments to over 51,000 patients struggling with depression.
Ticker SymbolSTIM
CompanyNeuronetics Inc
CEOMr. Keith J. Sullivan
Websitehttps://neurostar.com/neuronetics/
Related Instruments
+1.21%
+0.23%
-0.75%
+0.95%
+1.47%
-2.01%
+0.55%
+1.24%
-1.30%
+0.93%
+1.80%
+1.48%
-1.38%
+2.42%
+0.62%
+4.88%
+0.41%
+1.19%
-0.11%
+3.36%
